- Companies
- IVX Health
IVX Health Funding, Investors & Competitors
IVX Health has raised $136M across 3 funding rounds, most recently a $100M Series F in September 2021.
Last IVX Health funding round
$100M
Series F · Sep 2021
Cumulative funding IVX Health raised
$136M
across 3 funding rounds
Key investors in IVX Health
McKesson Ventures
Health Velocity Capital
Nueterra Capital
Great Hill Partners
Linden Capital Partners
Crimsonox Capital
About IVX Health
IVX Health is a provider of outpatient infusion therapy centers treating chronic conditions like rheumatoid arthritis and Crohn's disease. Operating as Infusion Express in Kansas City, Philadelphia, Chicago, and San Francisco, its suites feature private recliners and Wi-Fi. IVX Health administers biologics from manufacturers including AbbVie and Janssen to patients nationwide.
Founded
2012
HQ
Website
Status
Privately held
Customer focus
B2C
Revenue model
Services
IVX Health Funding History
IVX Health has raised a total of $136M across 3 funding rounds.
IVX Health's first fundraising round was a $14M Series B in October 2017. The most recent completed round was a $100M Series F in September 2021.
IVX Health funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Sep 2021 | Series F | Great Hill Partners (lead); McKesson Ventures; Health Velocity Capital; Linden Capital Partners; Nueterra Capital | $100M | IVX Health, a Nashville-based national provider of outpatient infusion centers, completed a $100 million Series F minority growth investment led by Great Hill Partners on September 21, 2021. Existing investors including Linden Structured Capital, McKesson Ventures, Health Velocity Capital, and Nueterra Capital participated. At the time, IVX Health operated over 50 infusion centers across 16 markets, specializing in pharmaceutical care for patients with complex chronic conditions such as multiple sclerosis, Crohn's disease, and rheumatoid arthritis. The funding is designated to accelerate entry into new markets starting in 2022, aiming to expand its unique clinical model and patient-centered amenities as an alternative to crowded hospital infusion rooms. IVX Health positions itself at an inflection point in infusion therapy, driven by rising autoimmune diagnoses, patient choice trends, and innovative therapies. Great Hill Managing Director Mark Taber joined the board and highlighted the company's disruption of biologic infusion and injection therapy, creating efficiencies in the U.S. healthcare system. CEO Doug Ghertner emphasized providing world-class service and clinical excellence to address care shortages. The investment supports collaborations with healthcare ecosystem providers to enhance patient and referring provider experiences. TripleTree advised Great Hill on the deal, aligning with the firm's focus on high-growth healthcare companies. |
| Aug 2019 | Series C | Health Velocity Capital (lead); McKesson Ventures (lead); Crimsonox Capital; Nueterra Capital | $23M | IVX Health, formerly Infusion Express, operates a network of outpatient infusion centers providing IV infusions and injection services for patients with chronic conditions like multiple sclerosis, rheumatoid arthritis, and Crohn's disease. The company focuses on patient-centered care in private suites, avoiding hospital settings, with services including insurance verification, prior authorization, oncology supportive care, and revenue cycle management. As of 2019, it had centers in markets like Kansas City, Philadelphia, Chicago, and San Francisco, planning expansions to Nashville, Harrisburg, and Columbus. On August 5, 2019, Infusion Express raised $22.5 million in a funding round co-led by McKesson Ventures and Health Velocity Capital, with participation from Nueterra Capital and new investor CrimsoNox Capital. This round supported accelerated nationwide expansion of its physical footprint in existing markets and entry into new ones. The company rebranded to IVX Health following the raise, with existing centers transitioning to the new brand in Q4 2019 and all new centers opening under IVX Health. Later developments include a prior $13.5 million Series B in 2017 led by McKesson Ventures with Health Velocity Capital, a Series D in 2020, and a $100 million Series F in September 2021 from Great Hill Partners, bringing total funding to around $136M-$166M across rounds. |
| Oct 2017 | Series B | McKesson Ventures (lead) | $14M | - |
Who has invested in IVX Health?
6 investors have backed IVX Health across its funding rounds, including McKesson Ventures, Health Velocity Capital, Nueterra Capital, Great Hill Partners, Linden Capital Partners and Crimsonox Capital.
Lead investors include Great Hill Partners, Health Velocity Capital and McKesson Ventures.
IVX Health Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 3 | Lead | Oct 2017 | ||
| 2 | Lead | Aug 2019 | ||
| 2 | Participant | Aug 2019 | ||
| 1 | Participant | Aug 2019 | ||
This data is available for Pro users. Sign up to see all 6 IVX Health investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by IVX Health
IVX Health has acquired 1 company to date.
Last acquisition by IVX Health was on October 14th 2020. IVX Health acquired Precisionhc for undisclosed valuation.
Latest Acquisitions by IVX Health
| Description | Precisionhc is a provider of infusion therapy services for recurring intravenous and injectable treatments. Operating in the United States, the company administers therapies for chronic conditions including immune disorders, pain management, and hydration needs. It maintains ambulatory infusion suites in multiple states, emphasizing patient-centered care with home delivery options for eligible prescriptions. |
| HQ Country | |
| HQ City | Nashville, TN |
| Deal Date | 14 Oct 2020 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all IVX Health acquisitions and their M&A valuation multiples. Start Free Trial | |
IVX Health Competitors
IVX Health competitors include listed companies like Fresenius, Fortis Healthcare, UnitedHealth Group and Thermo Fisher Scientific, and private ones like Gastro Health and Myhealth Medical Group.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $26B | $4.2B | $30B | 1.6x | ||
| Publicly listed | $943M | $215M | $7B | 7.1x | ||
| Private | - | - | $900M | - | ||
| Private | - | $15M | $134M | - | ||
| Publicly listed | $448B | $23B | $337B | 0.9x | ||
| Publicly listed | $45B | $11B | $243B | 6.0x |
IVX Health Public Comps
IVX Health is still privately-owned, but its public comps include UnitedHealth Group, Thermo Fisher Scientific, Danaher, HCA Healthcare, Becton Dickinson, Hoya, Alcon, Fresenius, Mindray and Medline.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $448B | $23B | 0.9x | 0.9x | 16.7x | 13.3x | |||
| $45B | $11B | 6.3x | 6.0x | 26.8x | 23.6x | |||
| $25B | $6.9B | 7.0x | 6.6x | 24.8x | 21.1x | |||
| $76B | $16B | 1.9x | 1.9x | 9.4x | 9.4x | |||
| $22B | $4.9B | 3.0x | 3.4x | 13.3x | 11.6x | |||
| $6.4B | $2.5B | 7.1x | 7.2x | 18.2x | 18.6x | |||
| $10B | $2.6B | 3.4x | 3.3x | 13.4x | 12.5x | |||
| $26B | $4.2B | 1.6x | 1.6x | 10.1x | 9.4x | |||
This data is available for Pro users. Sign up to see all IVX Health competitors and their valuation data. Start Free Trial | ||||||||
Common questions about IVX Health
| When was IVX Health founded? | IVX Health was founded in 2012. |
| Where is IVX Health headquartered? | IVX Health is headquartered in United States. |
| Is IVX Health publicly listed? | No, IVX Health is a private, VC-backed company. |
| How much funding has IVX Health raised? | IVX Health has raised $136M across 3 funding rounds. |
| What was IVX Health's last funding round? | IVX Health's last funding round was a $100M Series F in September 2021, led by Great Hill Partners. |
| Who are IVX Health's investors? | IVX Health's investors include McKesson Ventures, Health Velocity Capital, Nueterra Capital, Crimsonox Capital, Linden Capital Partners and Great Hill Partners. |
| Which companies are comparable to IVX Health? | Companies comparable to IVX Health include Fresenius, Fortis Healthcare, Gastro Health, Myhealth Medical Group, UnitedHealth Group and Thermo Fisher Scientific. |
| How many companies has IVX Health acquired? | IVX Health has acquired 1 company, including Precisionhc. |
See companies similar to IVX Health
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




